Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-05-02
2006-05-02
Devi, S. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S402000, C530S412000, C530S421000, C435S962000, C514S006900, C424S195110, C525S054100
Reexamination Certificate
active
07038016
ABSTRACT:
The present invention employs a dissolved activated polyethylene glycol (aPEG) or related molecule that has been passed through a filtration means for the substantial reduction of bioburden or endotoxin levels in the aPEG solution. The resulting filtered aPEG solution can be used for the preparation of a PEGylated hemoglobin solution containing substantially reduced levels of bioburden or endotoxin.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4229571 (1980-10-01), Katsunuma
patent: 4831012 (1989-05-01), Estep
patent: 4929354 (1990-05-01), Meyering et al.
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5234903 (1993-08-01), Nho et al.
patent: 5256559 (1993-10-01), Maraganore et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5464814 (1995-11-01), Sehgal et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5478738 (1995-12-01), Goldstein et al.
patent: 5741894 (1998-04-01), Azari et al.
patent: 5840852 (1998-11-01), Rausch et al.
patent: 5900402 (1999-05-01), Shorr
patent: 6017943 (2000-01-01), Acharya et al.
patent: 6150507 (2000-11-01), Houtchens et al.
patent: 2004/0067898 (2004-04-01), Somberg et al.
patent: 53038617 (1978-04-01), None
patent: WO 90/15613 (1990-12-01), None
patent: WO 02/44214 (2002-06-01), None
Talarico et al. Biochim. Biophys. Acta 1476: 53-65, 2000.
Zalipsky et al. J. Macromol. Sci. Chem. A21: 839-845, 1984.
Woghiren et al. Bioconj. Chem. 4: 314-318, 1993.
Greenwald et al. Bioconjugate Chem. 7: 638-641, 1996.
Blume et al. Biochim. Biophys. Acta 1029: 91-97, 1990.
Abuchowski et al. J. Biol. Chem. 252: 3578-3581, 1977.
Iwashita, Y., et al., “A New Resuscitation Fluid ‘Stabilized Hemoglobin’ Preparation and Characteristics,”Biomaterials, Artificial Cells, and Artificial Organs, 1988, pp. 271-280, vol. 16(1-3), Marcel Dekker, Inc.
Iwashita, Y., et al., “Relationship Between Chemical Properties and Biological Properties of Pyridoxalated Hemoglobin-Polyoxyethylene,”Biomaterials, Artificial Cells, and Artificial Organs, 1992, pp. 299-307, vol. 20(2-4), Marcel Dekker, Inc.
Sakai, H., et al., “Surface Modification of Hemoglobin Vesicles with Poly(ethyleneglycol) and Effects on Aggregation, Viscosity, and Blood Flow During 90% Exchange Transfusion in Anesthetized Rats,”Bioconjugate Chemistry, 1997, pp. 23-30, vol. 8, American Chemical Society, USA.
Sakai, H., et al., “Synthesis and Physiocochemical Characterization of a Series of Hemoglobin-Based Oxygen Carriers: Objective Comparison Between Cellular and Acellular Types,”Bioconjugate Chemistry, 2000, pp. 56-64, vol. 11, American Chemical Society, USA.
Miles, P., et al., “Detection of Residual Polyethylene Glycol Derivatives in Pyridoxylated-Hemoglobin-Polyoxyethylene Conjugate,”Artificial Cells, Blood Substitutes, and Immobilization Biotechnology,1997, pp. 315-326, vol. 25(3), Marcel Dekker, Inc., USA.
Privalle, C., et al., “Pyridoxalated Hemoglobin Polyoxyethlene: a Nitric Scavenger with Antioxidant Activity for the Treatment of Nitric Oxide-Induced Shock,”Free Radical Biology&Medicine, 2000, pp. 1507-1517, vol. 28 (10), Elsevier Science, Inc. USA.
Talarico, T., et al., “Autoxidation of Pyridoxalated Hemoglobin Polyoxyethylene Conjugate,”Biochemical and Biophysical Research Communications, 1998, pp. 354-358, vol. 250(2), Academic Press, USA.
Matsumura, S., “Large Scale Production and Characterization of Lyophilized Pyridoxalated Hemoglobin-Polyoxyethylene (PHP),”Biomat., Art. Cells&Immob. Biotech., 1992, vol. 20(2-4), pp. 435-438.
Talarico, T.L., “Comparability Analysis to Support a Manufacturing Site Change and Process Modifications for a Biopharmaceutical: A Regulatory Submission Case Study,”BioPharm, 1999, vol. 12(1), pp. 42-47.
Stacey Cyrus John
Talarico Todd Lewis
Alston & Bird LLP
Apex Bioscience, Inc.
Devi S.
LandOfFree
Methods for purification of an activated PEG solution and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for purification of an activated PEG solution and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for purification of an activated PEG solution and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3644724